Fig. 2: Kaplan-Meier estimates for the PET-2-negative per-protocol population. | Leukemia

Fig. 2: Kaplan-Meier estimates for the PET-2-negative per-protocol population.

From: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Fig. 2

A Progression-free survival. B Cumulative incidence of in-field recurrences. C Cumulative incidence of second primary malignancies. D Overall survival. Abbreviations: PFS progression-free survival, CMT combined-modality treatment, ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine, SPM second primary malignancy.

Back to article page